ReviewMolecular biotechnology2012
Development of vaccine delivery vehicles based on lactic acid bacteria.
Review in Molecular biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer.International journal of nanomedicine · 2026Review
- Progress in African Swine Fever Vector Vaccine Development.International journal of molecular sciences · 2025Review
- Recombinant L. lactis vaccine LL-plSAM-WAE targeting four virulence factors provides mucosal immunity against H. pylori infection.Microbial cell factories · 2024Article
- Pivotal role ofFrontiers in medicine · 2024Review
- Protective effects of engineeredFrontiers in veterinary science · 2024Article
- Changes in Gut Microbiota by theFrontiers in cellular and infection microbiology · 2022Article
- Genetically engineered bacterium: Principles, practices, and prospects.Frontiers in microbiology · 2022Review
- Oral Immunization With a M Cell-Targeting RecombinantFrontiers in immunology · 2022Article
- Genetic tools for the development of recombinant lactic acid bacteria.Microbial cell factories · 2021Review
- Article
- Impact of oral probiotic Lactobacillus acidophilus vaccine strains on the immune response and gut microbiome of mice.PloS one · 2019Article
- Synthetic Biology Approaches to Engineer Probiotics and Members of the Human Microbiota for Biomedical Applications.Annual review of biomedical engineering · 2018Review
- Analysis of Immune Responses in Mice Orally Immunized with Recombinant pMG36e-SP-TSOL18/Journal of immunology research · 2018Article
- A review on Lactococcus lactis: from food to factory.Microbial cell factories · 2017Review
- Immunogenic Properties of Lactobacillus plantarum Producing Surface-Displayed Mycobacterium tuberculosis Antigens.Applied and environmental microbiology · 2017Article
- Lactobacillus plantarum producing a Chlamydia trachomatis antigen induces a specific IgA response after mucosal booster immunization.PloS one · 2017Article
- Lactobacillus plantarum displaying CCL3 chemokine in fusion with HIV-1 Gag derived antigen causes increased recruitment of T cells.Microbial cell factories · 2015Article
- Article
- Mucosal Lactobacillus vectored vaccines.Human vaccines & immunotherapeutics · 2013Review
- Modern approaches in probiotics research to control foodborne pathogens.Advances in food and nutrition research · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Live recombinant bacteria represent attractive antigen delivery systems able to induce both mucosal and systemic immune responses against heterologous antigens. The first live recombinant bacterial vectors developed were derived from attenuated pathogenic microorganisms. In addition to the difficulties often encountered in the construction of stable attenuated mutants of pathogenic organisms, attenuated pathogens may retain a residual virulence level that renders them unsuitable for the vaccination of partially immunocompetent individuals such as infants, the elderly or immunocompromised patients. As an alternative to this strategy, non-pathogenic food-grade lactic acid bacteria (LAB) maybe used as live antigen carriers. This article reviews LAB vaccines constructed using antigens other than tetanus toxin fragment C, against bacterial, viral, and parasitic infective agents, for which protection studies have been performed. The antigens utilized for the development of LAB vaccines are briefly described, along with the efficiency of these systems in protection studies. Moreover, the key factors affecting the performance of these systems are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.